ReviewBrain pathology (Zurich, Switzerland)2025
Posterior pituitary tumors and other rare entities involving the pituitary gland.
Review in Brain pathology (Zurich, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A third ventricular floor-associated TTF-1-positive posterior pituitary tumor: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Posterior Pituitary and Hypothalamic Neuronal Tumors in the 5th WHO Classification: Molecular Insights, Diagnostic Markers, and Clinical Management.International journal of molecular sciences · 2026Review
- Endoscopic endonasal approach for rare sellar/parasellar pathologies: Insights from a neurosurgical perspective.Neurosurgical review · 2025Article
- Primary papillary epithelial tumor of the sella harboring an EZH2 Y646F mutation.Acta neuropathologica · 2025Article
- Histopathological Types, Clinical Presentation, Imaging Studies, Treatment Strategies, and Prognosis of Posterior Pituitary Tumors: An Updated Review.Journal of clinical medicine · 2025Review
- Posterior pituitary tumors: an entity unto itself.Pituitary · 2025Article
- Posterior pituitary tumors and other rare entities involving the pituitary gland.Brain pathology (Zurich, Switzerland) · 2025Review
- The 5th Edition of the WHO Classification of Pituitary Tumors: Strengths and limitations.Brain pathology (Zurich, Switzerland) · 2025Article
- Reply to letter by Melmed et al.Brain pathology (Zurich, Switzerland) · 2025Article
- Oncocytic pituicytoma in a patient with Cushing's disease: a case report and narrative literature review.Frontiers in endocrinology · 2025Review
- Predictive model of delayed hyponatremia after endoscopic endonasal transsphenoidal resection of pituitary adenoma.Frontiers in human neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-neuroendocrine tumors account for around 10% of all primary neoplasms of the sella. If meningiomas, craniopharyngiomas, and germ cell tumors are excluded, the remaining lesions include a broad spectrum of uncommon, benign, and aggressive, often diagnostically challenging lesions. This review aims to summarize the essential clinicopathological features of tumors of the posterior pituitary gland, infundibulum spectrum expressing thyroid transcription factor 1, and primary sellar atypical rhabdoid teratoid tumor, and provide the criteria for their diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.